FinTechsDepot FinTechsDepot - Empowering FinTech Futures: Where Knowledge Fuels Innovation.

  • HOME
  • ARTICLES
    • Digital banking
  • RESOURCES
    • Whitepaper
    • Infographics
  • GLOBENEWSWIRE NEWS
  • EVENTS
    • Upcoming conference
    • Past Conference
    • Webinar
  • Contact Us
FinTechsDepot
  • Home
  • Admin
  • Page 30

Author

Admin 425 posts 0 comments

Whitepaper

Mosaicx Conversational AI for Financial Services

Admin Apr 15, 2025
Improve the patient experience with conversational AI for healthcare. Mosaicx provides insightful and interactive…
Featured News

How to Save Tax in 2025: Smart Tips for Salaried Employees, Business Owners &…

Admin Apr 14, 2025
Paying taxes is a civic duty—but no one wants to pay more than they legally have to. Whether you're a salaried…
Articles

How to Save Tax Using Market-Linked Products—ELSS

Admin Apr 11, 2025
Tax saving is a priority for most individuals, especially during the financial year-end when everyone is…
Past Conference

Predict 2025: What The National Payments Vision Means For The UK

Admin Apr 10, 2025
Predict 2025: What the National Payments Vision Means for the UK is a must-attend event for professionals in the…
Whitepaper

The future of financial services: better customer experiences start with…

Admin Apr 9, 2025
Over the last few years, consumers have shown extraordinary resilience through much uncertainty. Many have adapted…
Whitepaper

How Finance & Accounting Teams Can Enable Digital Transformation

Admin Apr 8, 2025
Finance and accounting leaders are increasingly being called to do more and serve as strategic advisors to the…
Featured News

Stock Market Crash: ₹13 Lakh Crore Investor Wealth Wiped Out as Markets Plunge

Admin Apr 7, 2025
Today, April 7, 2025, global stock markets experienced significant declines, primarily driven by escalating trade…
Whitepaper

Buy Now, Pay Later: Market trends and consumer impacts

Admin Apr 2, 2025
Consumers have long used credit instruments to purchase goods and services. In recent years, a fast-growing…
Whitepaper

2025 Retail Banking Report

Admin Apr 1, 2025
Get more insights: 2025 World Retail Banking Report from Capgemini 67% of banking executives say prompt,…
Whitepaper

New global retail banking data

Admin Mar 31, 2025
Explore what’s new in retail banking: Download new Capgemini research Only 9% of prospects convert to…
Older Posts
Newer Posts

    SUBSCRIBE NOW


    Via Email
    Via Telephone


    I Agree. I would like to share my information with FinTechsDepot & their partners so that I can receive relevant information about products, services, & offers.

    RECENT POST

    • Future of Finance: Review on the outlook for the UK financial system
    • FinTech and Employee F&F Settlement: How Digital Financial Platforms Are Transforming the Employee Exit Process
    • How AI and Digital Innovation Are Transforming the Future of the FinTech Industry
    • The Power of Ecosystems for Banking
    • The Rise of Fintech: Transforming the Financial Landscape

    ARTICLE

    Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
    2026-08-13T20:30:00Z
    Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027


    Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
    2026-08-13T20:25:51Z
    Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the...


    Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
    2026-08-13T20:20:00Z
    -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 ---- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates anticipated in 2026...


    Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
    2026-08-13T20:15:00Z
    TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three...


    Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
    2026-08-13T20:15:00Z
    AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027


    Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
    2026-08-13T20:15:00Z
    Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding


    Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey
    2026-08-13T20:15:00Z
    A patient-centered initiative focused on education, connection, and support


    Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
    2026-08-13T20:15:00Z
    HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today...


    Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
    2026-08-13T20:10:00Z
    Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track


    Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
    2026-08-13T20:06:35Z
    MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today...


    Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
    2026-08-13T20:05:00Z
    NEW HAVEN, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights.


    Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    2026-08-13T20:05:00Z
    RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions...


    Glass House Brands Reports Second Quarter 2026 Financial Results
    2026-08-13T20:05:00Z
    LONG BEACH, Calif. and TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (NYSE: GLAS), one of the fastest-growing cannabis...


    Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    2026-08-13T20:05:00Z
    BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that...


    Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
    2026-08-13T20:05:00Z
    Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026


    MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
    2026-08-13T20:05:00Z
    ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial...


    ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
    2026-08-13T20:05:00Z
    PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf...


    CapsoVision Reports Second Quarter 2026 Financial Results
    2026-08-13T20:05:00Z
    SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and...


    Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update
    2026-08-13T20:05:00Z
    Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new market opportunities for protein sequencing


    4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
    2026-08-13T20:05:00Z
    EMERYVILLE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to...


    CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights  
    2026-08-13T20:05:00Z
    Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this...


    Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
    2026-08-13T20:05:00Z
    Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter


    Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
    2026-08-13T20:05:00Z
    DEER PARK, Ill., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...


    Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
    2026-08-13T20:05:00Z
    Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025


    Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    2026-08-13T20:05:00Z
    SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its...


    Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
    2026-08-13T20:05:00Z
    All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026


    Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
    2026-08-13T20:05:00Z
    ~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~


    Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
    2026-08-13T20:05:00Z
    – Net cash used in operating activities only $319K in the second quarter –– Arcadia closes $4 million private placement; ends second quarter with $4.2 million in cash –– July...


    Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
    2026-08-13T20:05:00Z
    The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department...


    Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
    2026-08-13T20:05:00Z
    GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced a $15 million growth capital financing...

    Copyright © 2026 | FinTechsDepot | All Rights Reserved |
    Privacy Policy | Unsubscribe
    Sign in

    Welcome, Login to your account.

    Forget password?
    Sign in

    Recover your password.

    A password will be e-mailed to you.